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A B S T R A C T
Background: The optimal preoperative therapeutic strategy for patients with coronary artery disease
(CAD) is an important concern in the era of drug-eluting stents and antiplatelet therapy. However, there
are few studies about the impact of prior percutaneous coronary intervention (PCI) on perioperative
major adverse cardiac events (MACEs) and bleeding events associated with oral antiplatelet therapy.
The aim of this study was to examine the risks and beneﬁts of performing PCI before non-cardiac surgery
(NCS) in patients with CAD.
Methods: We investigated 130 patients who had angiographically signiﬁcant and stable CAD and
underwent NCS after index coronary angiography. We divided the patients into two groups: patients
undergoing PCI with coronary stenting (PCI group), and those not undergoing PCI before NCS (no-PCI
group), and compared the MACEs and bleeding events within 30 days from NCS between the groups.
Results: There were 53 and 77 patients in the PCI and no-PCI groups, respectively. MACEs were
observed in 2 patients (3.8%) in the PCI group and 3 patients (3.9%) in the no-PCI group (p = 0.97),
whereas bleeding events were observed in 10 (18.9%) and 8 patients (10.4%) in the PCI and no-PCI
groups, respectively (p = 0.17). There were no signiﬁcant differences between the two groups in terms
of MACEs and bleeding events.
Conclusions: The rate of MACEs following NCS was not signiﬁcantly different between the PCI and no-PCI
groups, while the rate of bleeding events was higher in the PCI group without reaching statistical
signiﬁcance. This study suggests that patients with stable CAD may be able to safely undergo NCS
without revascularization even in the presence of signiﬁcant coronary artery stenosis.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The optimal preoperative management for patients with
coronary artery disease (CAD) is an important concern. However,
there are currently limited data about the efﬁcacy of revasculari-
zation before non-cardiac surgery (NCS) in patients with CAD.
Previous randomized trials examining the role of revascularization
prior to NCS showed that prior revascularization did not improve
clinical outcomes in patients with stable CAD [1,2]. However, these* Corresponding author at: 1-847 Amanuma, Omiya-ku, Saitama City, Saitama
330-8503, Japan. Tel.: +81 48 647 2111; fax: +81 48 648 5188.
E-mail address: wada1006@hotmail.com (H. Wada).
http://dx.doi.org/10.1016/j.jjcc.2014.12.008
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsstudies were conducted in the setting of vascular surgery only,
and the mode of revascularization included both percutaneous
coronary intervention (PCI) and coronary artery bypass grafting
(CABG). Therefore, the efﬁcacy of PCI prior to various types of NCSs
has not been fully examined.
NCS for patients who have undergone successful PCI with stent
placement is associated with a number of problems, including
bleeding complications resulting from perioperative oral anti-
platelet therapy and stent thrombosis (ST), which is a catastrophic
occurrence associated with an interruption of oral antiplatelet
therapy [3]. Several previous studies have reported on how to
manage patients with coronary stents when they present for
NCS. The American College of Cardiology (ACC)/American Heart
Association (AHA) and European Society of Cardiology (ESC) reserved.
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patients with coronary stents have completed an appropriate
course of dual antiplatelet therapy (DAPT) [4–6]. However, to date,
there have been few studies comparing the perioperative major
adverse cardiac and bleeding events, including ST, between
patients with CAD undergoing PCI and those not undergoing PCI
prior to NCS.
The purpose of this study was to compare the perioperative
major adverse cardiac events (MACEs) between patients with CAD
undergoing PCI with coronary stenting and those not undergoing
PCI before NCS. Moreover, we also compared the rates of
perioperative bleeding events and examined the risks and beneﬁts
associated with performing PCI before NCS.
Methods
Study population
We identiﬁed 1426 consecutive patients who underwent
coronary angiography (CAG) and were diagnosed with angio-
graphically signiﬁcant CAD between January 1, 2010 and Decem-
ber 31, 2011 at Saitama Medical Center, Jichi Medical University.
Patients who did not receive NCS (n = 1003) or who received
cardiac surgery, including CABG (n = 176), were excluded. Fur-
thermore, patients diagnosed with acute coronary syndrome
(n = 33), ventricular ﬁbrillation (n = 2), and pulseless electrical
activity (n = 1) at the time of CAG were also excluded. In addition,
we excluded patients with <90% stenosis, patients without main
branch lesions, and patients with only distal lesions (n = 81).
Finally, 130 patients with 90% stenosis in the proximal or mid
main branches were included in the analysis. Patients who
underwent PCI after CAG and subsequently underwent NCS were
deﬁned as the PCI group, whereas patients who did not undergo
PCI after CAG were deﬁned as the no-PCI group (Fig. 1). NCS was
deﬁned as the ﬁrst non-cardiac surgical procedure after the CAG,
and classiﬁed into high-, intermediate-, or low-risk groups in
accordance with the ESC guidelines for preoperative cardiac
risk assessment and perioperative cardiac management in NCSPCI group
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Fig. 1. Flowchart. CAD, coronary artery disease; NCS, non-ca[6]. Patients who received antiplatelet or anticoagulant therapy
within 5 days before NCS were deﬁned as being on preoperative
antiplatelet or anticoagulant therapy. Patient data were obtained
from their medical records and retrospectively analyzed. The
study protocol was approved by the Ethics Committee of Saitama
Medical Center, Jichi Medical University.
Coronary revascularization strategy
In our institution, we usually follow the current guidelines
when patients are referred for revascularization [7]. PCI is
considered for patients with 1- or 2-vessel disease, whereas CABG
is considered for patients with 3-vessel or left main disease, and
occasionally for patients with 1- or 2-vessel disease, including the
proximal left anterior descending artery (LAD). With respect to
the stent type, drug-eluting stents (DES) are selected for small
vessels (reference diameter 2.5 mm) or diffuse lesions (>30 mm),
whereas bare metal stents (BMS) are selected for large vessels
(reference diameter >4.0 mm) or short lesions (<20 mm).
With regard to the strategy of coronary revascularization for
patients scheduled for NCS, there is no deﬁnite rule in our
institution. However, we usually divide NCS into four subcate-
gories, namely surgeries for early-stage cancer, advanced-stage
cancer, stable disease (non-cancer), and unstable disease (non-
cancer). In NCS for early-stage cancer, DES can be used for PCI in
most cases; however, we tend to prefer BMS implantation. On the
other hand, in NCS for stable disease (non-cancer), we generally
do not hesitate to use DES. Thus, for these subcategories, we
just follow the clinical guidelines in our institution. Conversely,
for advanced-stage cancer, we generally prioritize the NCS over
coronary revascularization. If the patients have 99% culprit
coronary artery stenosis with poor collateral ﬂow, we perform
PCI with BMS. In NCS for unstable disease (non-cancer), we
prioritize NCS over coronary revascularization as long as the
minimum exercise capacity (4 metabolic equivalents) is main-
tained. If the exercise capacity is <4 metabolic equivalents, we
prefer to perform coronary revascularization using BMS or CABG
before the NCS. In addition, we discuss the indication or strategyy
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Table 1
Baseline characteristics.
PCI (n = 53) No-PCI (n = 77) p
Age (years) 73 (66–77) 71 (64–77) 0.31
Men 45 (84.9) 65 (84.4) 0.94
Weight (kg) 62.4  10.5 60.6  9.64 0.30
Height (cm) 162.8  8.21 160.9  7.06 0.16
Hypertension 42 (79.2) 56 (72.7) 0.40
Dyslipidemia 29 (54.7) 42 (54.5) 0.99
Diabetes 22 (41.5) 43 (55.8) 0.11
Active smoking 6 (11.3) 17 (22.1) 0.11
Stroke 7 (13.2) 12 (15.6) 0.71
PVD 12 (22.6) 26 (33.8) 0.17
Previous MI 11 (20.8) 19 (24.7) 0.60
Previous PCI 53 (100) 22 (28.6) <0.001
Previous CABG 2 (3.8) 9 (11.7) 0.11
CHD 8 (15.1) 16 (20.8) 0.41
Hemodialysis 4 (7.5) 9 (11.7) 0.44
BUN (mg/dl) 17.0 (14.0–24.0) 18.0 (14.0–24.5) 0.61
Creatinine (mg/dl) 0.98 (0.74–1.6) 0.94 (0.78–1.3) 0.93
Hemoglobin (g/dl) 12.4  1.88 12.7  2.08 0.47
Medication
b-Blockers 31 (58.5) 42 (54.5) 0.66
Statins 46 (86.8) 48 (62.3) 0.002
ACEIs or ARBs 42 (79.2) 44 (57.1) 0.009
Nitrates 9 (17.0) 20 (26.0) 0.23
Anticoagulant agents 7 (13.2) 7 (9.1) 0.46
Antiplatelet agents
None 6 (11.3) 27 (35.1) 0.002
Aspirin alone 29 (54.7) 40 (51.9) 0.76
Thienopyridine alone 1 (1.9) 1 (1.3) 0.79
DAPT 17 (32.1) 9 (11.7) 0.004
Heparin-alternative therapy 17 (32.1) 15 (19.5) 0.10
Duration from CAG
to NCS (months)
<0.001
0–3 20 (37.7) 63 (81.8)
4–6 5 (9.4) 2 (2.6)
7–12 12 (22.6) 7 (9.1)
>12 16 (30.2) 5 (6.5)
Values are number of patients (%), mean  SD or median (interquartile range).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CAG, coronary
angiography; CHD, congestive heart disease; DAPT, dual antiplatelet therapy; MI,
myocardial infarction; NCS, non-cardiac surgery; PCI, percutaneous coronary
intervention; PVD, peripheral vascular disease.
Table 2
Angiographic ﬁndings.
PCI (n = 53) No-PCI (n = 77) p
Number of vessels with stenosis 0.52
SVD 22 (41.5) 34 (44.2)
DVD 17 (32.1) 29 (37.7)
TVD 14 (26.4) 14 (18.2)
Location of stenosis
RCA 33 (62.3) 44 (57.1) 0.56
LAD 40 (75.5) 36 (46.8) 0.001
LCX 27 (50.9) 52 (67.5) 0.057
LMT 1 (1.9) 2 (2.6) 0.79
Graft 1 (1.9) 7 (9.1) 0.093
Quantitative coronary analysis
Lesion length (mm) 9.55 (7.48–11.8) 9.31 (6.70–13.8) 0.80
Reference diameter (mm) 2.18 (1.87–2.91) 2.17 (1.83–2.71) 0.47
Luminal diameter (mm) 0.72 (0.48–1.05) 0.68 (0.00–0.95) 0.10
% stenosis (%) 66.2 (55.4–76.7) 70.0 (58.4–100) 0.22
ACC/AHA classiﬁcation 0.26
Type A 19/102 (18.6) 18/140 (12.9)
Type B1 24/102 (23.5) 32/140 (22.9)
Type B2 27/102 (26.5) 30/140 (21.4)
Type C 32/102 (31.4) 60/140 (42.9)
Values are number of patients (%), number of lesions (%) or median (interquartile
range). There were 102 and 140 lesions in the PCI and no-PCI groups, respectively.
ACC, American College of Cardiology; AHA, American Heart Association; DVD,
double vessel disease; LAD, left anterior descending artery; LCX, left circumﬂex
artery; LMT, left main trunk; PCI, percutaneous coronary intervention; RCA, right
coronary artery; SVD, single vessel disease; TVD, triple vessel disease.
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case. Regarding the oral antiplatelet therapy, patients undergoing
BMS implantation receive aspirin (100 mg/day) and thienopyr-
idine (ticlopidine 200 mg/day or clopidogrel 75 mg/day) as DAPT
for at least 30 days, whereas patients undergoing DES implantation
receive DAPT for 6 months or longer in our institution. NCS is
usually scheduled 1 month (BMS) or 6–12 months (DES) following
stent implantation. Although thienopyridine is often discontinued,
aspirin is usually continued during the perioperative period.
However, the ﬁnal decisions regarding the therapy for coronary
stenosis (revascularization or medical therapy), the revasculariza-
tion strategy (CABG or PCI), the stent type (BMS or DES), and
the duration of antiplatelet therapy in the perioperative period are
made at each attending physician’s discretion.
Clinical outcomes
The clinical outcomes were deﬁned as any MACE or bleeding
event within 30 days from NCS. Any postoperative myocardial
ischemic event, ST, stroke, heart failure, cardiogenic shock, or
sudden death was considered as a MACE. ST was deﬁned according
to the Academic Research Consortium deﬁnition [8]. Bleeding
events were deﬁned according to the International Society of
Thrombosis and Hemostasis, and categorized as major or minor
bleeding [9]. Major bleeding was deﬁned as fatal bleeding,
bleeding that was symptomatic and occurred in a critical area
or organ, such as intracranial, intraspinal, intraocular, retroperito-
neal, pericardial, in a non-operated joint, or intramuscular with
compartment syndrome, bleeding causing a fall in hemoglobin
level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of
2 or more units of whole blood or red cells, bleeding warranting
treatment cessation, surgical site bleeding that required a second
intervention – open, arthroscopic, endovascular – and surgical site
bleeding that was unexpected and prolonged and/or sufﬁciently
large to cause hemodynamic instability. In other circumstances,
the bleeding was considered minor.
Statistical analysis
Continuous variables are expressed as mean  SD for normally
distributed variables or median (interquartile range) for nonparametric
variables. The normality of the data was assessed using the Shapiro–
Wilk test. Comparisons for normally distributed variables were
performed with independent samples unpaired t-test. Non-parametric
variables were analyzed with Mann–Whitney U-test. Categorical data
were presented as numbers (%) and analyzed using the chi-square
test. A value of p < 0.05 was considered statistically signiﬁcant. Data
were analyzed using SPSS version 19 (SPSS, Inc., Chicago, IL, USA).
Results
The baseline characteristics of the study patients are shown in
Table 1. PCI with coronary stenting before NCS was performed in 41%
of all patients (53/130). In the PCI group, DES and BMS implantations
were performed in 60% (32/53) and 40% (21/53) of the patients,
respectively. In the no-PCI group, revascularization after the NCS
was performed in 39% (30/77) of the patients. PCI with DES, PCI with
BMS, and CABG were performed in 20, 3, and 7 of these patients,
respectively. There were no differences between the PCI and no-PCI
groups, except for the preoperative medication such as statins,
angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers, or antiplatelet agents, and the duration from CAG to NCS.
The duration was signiﬁcantly longer in the PCI group, and patients
with DES implantation comprised the vast majority of patients
undergoing NCS 12 months or longer after the PCI (DES, 15; BMS, 1).
The angiographic ﬁndings of the index CAG are shown in Table 2. The
Table 3
Comparison of surgical risks between the PCI and no-PCI groups.
PCI (n = 53) No-PCI (n = 77) p
Surgical risks 0.64
High-risk 16 (30.2) 29 (37.7)
Intermediate-risk 16 (30.2) 19 (24.7)
Low-risk 21 (39.6) 29 (37.7)
Values are number of patients (%). PCI, percutaneous coronary intervention.
Table 4
Details regarding the NCS.
PCI (n = 53) No-PCI (n = 77) p
Types of surgery 0.035
Aortic and major vascular surgery 14 (26.4) 21 (27.3)
Peripheral vascular surgery 2 (3.8) 8 (10.4)
Abdominal 4 (7.5) 7 (9.1)
Carotid 0 (0) 1 (1.3)
Endovascular aneurysm repair 4 (7.5) 8 (10.4)
Head and neck surgery 7 (13.2) 1 (1.3)
Pulmonary 1 (1.9) 1 (1.3)
Urologic-major 0 (0) 1 (1.3)
Eye 6 (11.3) 2 (2.6)
Gynecology 0 (0) 1 (1.3)
Orthopedic-minor 3 (5.7) 2 (2.6)
Urologic-minor 5 (9.4) 2 (2.6)
Othersa 7 (13.2) 22 (28.6)
Operative time (min) 166 (55–273) 193 (107–266) 0.27
Unplanned surgery 4 (7.5) 2 (2.6) 0.19
Values are number of patients (%). NCS, non-cardiac surgery; PCI, percutaneous
coronary intervention.
a Others include cardiovascular implantable electronic device implantation,
skin cancer excision, arteriovenous ﬁstula construction for hemodialysis and
tracheotomy.
Table 5
Details regarding the MACEs and bleeding events within 30 days from NCS.
PCI (n = 53) No-PCI (n = 77) p
MACEs 2 (3.8) 3 (3.9) 0.97
Heart failure 0 1
Myocardial ischemia 0 1
Stroke 1 1
ST, possible 1 0
Bleeding events 10 (18.9) 8 (10.4) 0.17
Major bleeding 9 (17.0) 6 (7.8) 0.11
Minor bleeding 1 (1.9) 2 (2.6) 0.79
Blood transfusion 5 (9.4) 4 (5.2) 0.35
Bleeding sites
Surgical site 10 6
Gastrointestinal 0 2
Values are number of patients (%). MACE, major adverse cardiac event; NCS, non-
cardiac surgery; PCI, percutaneous coronary intervention; ST, stent thrombosis.
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compared with the no-PCI group. The surgical risks associated with
NCS are shown in Table 3. There were no differences relating to
surgical risk between the two groups. Comparisons of the types of
surgery, operative times, and frequency of unplanned surgery
between the groups are shown in Table 4, and details regarding the
MACEs and bleeding events within 30 days from NCS are shown in
Table 5. There were no signiﬁcant differences in the frequency of
MACEs and bleeding events between the two groups.
A representative case of severe multivessel CAD before NCS
is presented in Fig. 2. The CAG showed severe stenosis of the
proximal LAD and proximal right coronary artery. This 70-year-old
male patient did not undergo PCI and subsequently receivedFig. 2. A representative case of severe multivessel coronary artery disease before non-car
anterior descending artery (arrows) (A) and severe stenosis of the proximal right corocarotid endarterectomy within 3 months after the CAG. He was
treated with oral aspirin, b-blocker, statin, and angiotensin
receptor blocker in the preoperative period, and did not experience
any MACE or bleeding event.
Discussion
The ﬁndings of this study showed no signiﬁcant differences in
perioperative MACEs between patients with CAD undergoing PCI
with coronary stenting and those not undergoing PCI before NCS.
The bleeding event rate was higher in the patients undergoing PCI
before NCS without reaching statistical signiﬁcance.
The efﬁcacy of PCI prior to NCS is controversial. To date, there
have been two randomized controlled trials investigating the
beneﬁts of coronary revascularization before elective major
vascular surgery, although the revascularization procedures
included both PCI and CABG. The CARP (Coronary Artery
Revascularization Prophylaxis) trial, the ﬁrst randomized trial
among patients with stable CAD, showed that coronary artery
revascularization did not reduce the number of postoperative
myocardial infarctions, deaths, or days in the hospital within
30 days from NCS, although patients with stenosis of the left main
coronary artery or severe left ventricular dysfunction were
excluded [1]. The DECREASE (Dutch Echocardiographic Cardiac
Risk Evaluation Applying Stress Echo)-V study assessed the efﬁcacy
of preoperative coronary revascularization in patients with
extensive stress-induced ischemia, and showed that preoperative
coronary revascularization did not reduce all-cause mortality or
myocardial infarction within 30 days from NCS [2]. According todiac surgery. The coronary angiography showed severe stenosis of the proximal left
nary artery (arrow-head) (B).
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or no value in preventing perioperative cardiac events in patients
with stable CAD, although the veracity of the results of the
DECREASE-V study is controversial. Moreover, the ACC/AHA
guidelines also indicate that PCI before NCS is of no value in
preventing perioperative cardiac events in patients with stable
CAD, and the role of preoperative PCI appears limited to patients
with unstable active CAD [5]. The results of the present study also
showed no differences in the MACEs between the PCI and no-
PCI groups, supporting the recommendation of the ACC/AHA
guidelines.
The risk of MACEs, including ST, is notably increased when
surgery is performed early after stent implantation, owing to the
fact that stents are not endothelialized, and that an inﬂammatory
and prothrombotic state is induced by the surgical stress [4,10–
13]. Additionally, premature antiplatelet therapy discontinuation
has been identiﬁed as a predictor of ST in patients with coronary
stents [14]. Concerning bleeding events, DAPT appears to be
associated with a higher bleeding risk compared with single
antiplatelet therapy (SAPT) in patients undergoing PCI, although
few studies have investigated this association [15]. Yamamoto
et al. reported that the rate of bleeding events associated with NCS
in patients treated with DAPT was signiﬁcantly higher than that in
patients treated with SAPT (9.5% vs. 2.3%, p = 0.049) [16], and van
Kuijk et al. similarly reported that the risks of severe bleeding in
patients with coronary stents receiving DAPT and SAPT at the time
of NCS were 21% and 4%, respectively (p < 0.001) [17]. Thus, PCI
before NCS appears to be associated with a number of problems,
and the management of antiplatelet therapy to avoid excessive
bleeding while minimizing the risk of ST poses a dilemma. In this
study, only one case of possible ST was identiﬁed. Although the
bleeding event rate tended to be higher in the PCI group than in
the no-PCI group, there were no signiﬁcant differences between
the two groups. However, the number of patients included in the
present study was relatively low, and a signiﬁcant difference may
be found if we include a larger number of patients.
In this study, the duration from CAG to NCS was signiﬁcantly
longer in the PCI group, and 11 planned NCSs were delayed
speciﬁcally due to DES implantation. The ACC/AHA and ESC
guidelines recommend that elective NCS should be delayed until
patients with coronary stents have completed an appropriate
course of DAPT to prevent severe bleeding complications and ST
[5,6]. Our results suggest that prior PCI delayed NCS according to
the recommendation of these guidelines. Considering the com-
plexity of the perioperative management of patients with coronary
stents and delayed NCS caused by PCI, we suggest that patients
with stable CAD should undergo NCS before PCI.
Study limitations
First, this was a single-center, retrospective study. Therefore,
the possibility of selection bias cannot be excluded, and the care of
the patients was not controlled by a study protocol. Second,
patients who received minor surgery, such as ophthalmic surgery,
were included in our analysis. These patients may have a lower
risk of MACEs or bleeding events and their inclusion may have
affected the results of this study. Third, we did not have access
to information regarding the antiplatelet agents other than
aspirin and thienopyridine. The other antiplatelet agents might
have affected the risks of MACEs or bleeding events. Fourth,
we performed only morphological assessment of myocardial
ischemia and not functional assessment by stress myocardial
scintigraphy or measurement of fractional ﬂow reserve. Fifth, only
39% of the patients in the no-PCI group received revascularization
therapy after the NCS. The location and/or morphology of the
coronary lesions in the no-PCI group were originally consideredinappropriate for PCI, and this is likely the main reason for this low
proportion. Lastly, we only estimated the short-term prognosis of
the patients, and did not assess whether PCI could predict the long-
term clinical outcomes. Further longitudinal and prospective
studies are needed to address these issues.
Conclusions
This study showed that the rate of MACEs following NCS was
not signiﬁcantly different between patients undergoing and not
undergoing PCI prior to NCS, while the rate of bleeding events was
higher in the PCI group without reaching statistical signiﬁcance.
These ﬁndings suggest that patients with stable CAD can safely
undergo NCS without revascularization, even in the presence of
signiﬁcant coronary artery lesions.
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